News Hub | News Direct

All Industries


Article thumbnail News Release

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Benzinga

By Anthony Termini BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotechnology company involved in various clinical trials involving its patented approach for using stem cell therapy to treat a number of disorders. The company has, in recent months, issued updates on its earnings and operations, and it is developing a promising treatment program to treat diabetes and obesity. Quarterly Report Highlights The company issued its second quarter 2024 business update in August, and a number of announcements accompanied their reported financials. BioRestorative announced that preliminary clinical data related to its “Disc/Spine Program” showed meaningful signals and no notable safety markers in patients enrolled in a clinical study of BRTX-100 as a treatment for chronic lumbar disc disease. Also, following manufacturing/clinical process enhancements made by BioRestorative that tripled its monthly trial capacity, it guided that it was targeting completion of patient enrollment in the phase 2 BRTX-100 study in chronic lumbar disc disease (cLDD) by the end of 2024. The company also plans to provide additional preliminary data updates by then. Furthermore, BioRestorative said that it has also laid the foundation for the commercialization of its BioCosmeceuticals business, which could begin generating significant revenues this year. The company noted that it inked an agreement to supply its proprietary cell-based biologic serum to Cartessa Aesthetics, LLC. An analysis of the company’s June 30, 2024 Form 10-Q revealed a 19% improvement in year-over-year operations, with net loss narrowed to $2.5 million compared to a $3.1 million loss in the prior period. BioRestorative’s balance sheet showed some $14.7 million on hand at the end of June. Lance Alstodt, BioRestorative’s Chief Executive Officer, noted that these accomplishments “will provide additional financial flexibility” and bolster the company’s strategy to execute and accomplish important long-term goals. The quarterly report also discussed BioRestorative’s expansion of its core preclinical program for ThermoStem®. “Metabolic Program” Addresses Important And Lucrative Markets One of the more significant opportunities that BioRestorative is pursuing is related to its ThermoStem platform. Currently in preclinical testing, the intended therapy is to target obesity and metabolic disorders (like diabetes) using stem cells to generate a type of body fat that regulates metabolic homeostasis. A recent report from the Centers for Disease Control and Prevention demonstrates that nearly 42% of adults in the United States suffer from obesity. Those diagnosed with severe obesity were just over 9%. Furthermore, research conducted at Harvard University and George Washington University concluded that “adults with obesity spend an average of $1,861 more a year on medical costs than someone who doesn’t have obesity. People with severe obesity spend an average of $3,097 more.” According to investment firm Goldman Sachs, the worldwide market for obesity drugs could be $100 billion by 2030. And there is a link between obesity and diabetes. The American Heart Association says that obesity contributes to up to half of new diabetes cases annually in the United States. Treating this disease also represents a significant market opportunity for BioRestorative. Precedence Research expects the global diabetes drug market to reach about $132 billion by 2034. The combined market for obesity and diabetes drugs creates a significant opportunity for BioRestorative’s ThermoStem over the next decade. It is important to note that ThermoStem is not restricted to being only a standalone treatment. It may be used with drugs like Novo Nordisk’s (NYSE: NVO) Ozempic or Wegovy, or Eli Lilly’s (NYSE: LLY) Mounjaro, which are already approved for use to treat both obesity and diabetes. “We believe that ThermoStem has immense potential to develop both best-in-class and first-in-class therapies,” said Alstodt. Other Developments Related To BioRestorative’s Intellectual Property Portfolio Also accompanying BioRestorative’s business update announcement were comments related to its broad intellectual property portfolio. Previously published data from a study conducted at the University of Utah School of Medicine showed significant reductions in weight, triglyceride, and blood glucose levels compared to controls. The study also demonstrated that BioRestorative’s 3D scaffold was capable of retaining viable transplanted cells for at least five weeks post-implantation. In June, BioRestorative published a press release announcing that it had received notice of allowance from the Japanese Patent Office for a patent application related to ThermoStem. This is the fifth Japanese patent issued for the ThermoStem technology platform. “We are proactively expanding the already formidable ThermoStem intellectual property estate to help ensure long-term market exclusivity…” and “…this is demonstrated by this new patent allowance,” Alstodt remarked. The company also announced that it is currently involved in substantive discussions with at least one (undisclosed) regenerative medicine company regarding ThermoStem licensing. This, along with the Cartessa agreement, is why the company said that it “is poised to potentially enter into a stage of anticipated rapid growth.” Featured photo by qimono on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

AI Software Company Amesite Posts Its Largest Win In Community College Deal And Makes Natural Pivot To On-The-Job AI Support For Healthcare

Benzinga

By Meg Flippin, Benzinga Education is getting an overhaul thanks to artificial intelligence (AI) and companies like Amesite (NASDAQ: AMST). The Detroit-based AI software company develops products and platforms to improve online learning. Leveraging GPT-4, the AI system powering Bing and ChatGPT Plus, Amesite says that online courses can be added quickly, programs are adaptable and users stay engaged. That approach to learning is getting attention from educators, particularly with community colleges around the country. Maricopa Corporate College (MCOR) is part of the Maricopa Community College District (MCCCD), Arizona’s largest workforce developer. MCOR recently signed an agreement with Amesite. Expanding Its College Reach Amesite just inked a multiyear deal to provide programs through MCOR, to provide AI-based online training and development. With roughly 140,000 students, MCCCD is Arizona’s largest workforce developer, playing a central role in charting the future of the Greater Phoenix region. The school system produces the second-largest number of college graduates in Arizona and creates one out of every 28 jobs in Maricopa County, adding $7.9 billion to the economy. This exclusive agreement marks the biggest customer yet for the AI software company. It's exactly the type of enterprise Amesite is targeting. With a focus on community colleges, the company now counts seven institutions as customers offering students and faculty the Amesite LCE platform. Installations span the United States, with colleges in Alabama, Illinois, Louisiana, South Carolina, Tennessee, West Virginia and now, Arizona. Collectively, colleges that have chosen Amesite train over 200,000 learners each year, reports the company. "Our AI-powered solution enables professional learners to get information – and support – in real-time,” said Dr. Ann Marie Sastry, CEO of Amesite, in a press release announcing the deal with Maricopa. “We have long believed that AI-assisted professional training would replace traditional training and are pleased to see our solutions gaining acceptance, now with larger colleges. We are especially pleased to be the first to provide the right tools in this market." In Amesite’s vision for education and upskilling, learners aren’t taught in isolated silos but rather are part of a larger learning community. V6, the latest version of its learning platform, is the fruition of that AI-driven vision. It offers capabilities such as learning and creative assistants, and supports educational games, interactive learning experiences and other learning incentives to keep students engaged. V6 can integrate thousands of application programming interfaces (API), which means it works with most companies’ and schools’ programs. Setting Its Sights On Larger Markets But educating the workforce of tomorrow through community colleges isn’t the only thing Amesite is doing with its advanced AI. The company’s infrastructure and capabilities in AI programming can be easily deployed to provide on-the-job apps for different industries, including healthcare – specifically, the 5.2 million nurses in the U.S. who could benefit from some AI technology. In the spring, Amesite launched NurseMagic™, a proprietary AI app designed for nurses. With it, nurses can write nursing notes instantly, quickly translate medical terms into easy-to-understand language, create work emails, assist nurses in talking to patients with compassion, coach nurses on taking effective breaks during the day, provide key information about medications and collect instant feedback. It makes sense that Amesite would want to set its sights on nurses. Despite the over five million of them in the workforce, America is facing a shortage that’s projected to grow, not to mention the high burnout rate for this profession. Introducing technology that makes their lives easier not only improves their careers but saves hospitals and healthcare systems money. After all, burnout can cost a hospital $16,736 per nurse per year through retention challenges, sick days and training new replacement nurses. “Launching apps enables us to directly reach much larger audiences. We want to equip every nurse on the planet with tools that deliver immediate, qualified information and address the demands on their time while leveraging their expertise,” said Sastry at the time. A Continued Focus On Innovation Not one to rest on its laurels, since rolling out NurseMagic, Amesite has been adding to the app’s capabilities, working hard to ensure it maintains its competitive lead and becomes the leading app for nurses. Some of those enhancements include the ability to build and update a resume, write cover letters for job applications, create text that improves a nurse’s social profile on LinkedIn and other sites and create replies to employers that highlight the applicant’s strengths. With those enhancements, Amesite says it’s helping the 35% of nurses who indicate they may look for a new job in the next year. The app is also capable of creating nursing notes, a requirement for professionals ranging from CNAs and LPNs to APRN-CNPs and NPs which Amesite says takes up 40% of nurses’ time. The company also recently added the ability to upload and store study materials – including pdfs and video and audio files – to instantly create transcripts, summaries and even quizzes and flashcards, based on the material. Proof Is In The Accuracy All these enhancements to NurseMagic are only as good as the AI behind it and Amesite has that covered as well. The company reports the foundational model that powers NurseMagic achieved a 93% accuracy rate when tested with questions from two leading NCLEX prep providers’ test banks. The NCLEX exam is a standardized exam developed by the National Council of State Boards of Nursing (NCSBN) that nursing graduates must pass to obtain their nursing licenses in the United States and Canada. Accuracy is essential for the growing number of nurses using the app. In June, the app was released in beta. Within a week of the release, close to 1,200 individuals completed an onboarding survey and registered as users of NurseMagic. Since then, usage has continued to gain momentum. At last check, NurseMagic has users from all 50 U.S. states and six nations. User growth continued to expand rapidly after launch, up 830% month-over-month from June to July. It also has the support of some popular influencers in the nursing community, including Paige Slayton, a nurse influencer engaged by Amesite, with over 900,000 followers. "This is the fastest growth in usership that we have ever seen with any of our products,” said Sastry. “We are excited to be delivering a vital and useful tool to the largest segment of healthcare professionals and believe that NurseMagic TM will create a positive impact in healthcare and strong, sustainable revenue growth for Amesite." From education to healthcare, Amesite's AI-powered learning platform is empowering countless people and making professionals’ lives much easier. With a model that can be replicated for different industries and markets, Amesite is carving out its path to stand out in the AI-powered learning of tomorrow. Featured photo by Hush Naidoo Jade Photography on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Stotland Trucking LLC Expands Headquarters and Opens New Location in Abilene, TX

Apple Rush Company, Inc.

Apple Rush Company, Inc. (OTCpink:APRU), a leading player in the functional beverage industry, announces its subsidiary Stotland Trucking, LLC. a leading logistics provider renowned for its reliable delivery services, is thrilled to expand on its previous announcement of the expansion of its headquarters in Austin, TX. The company has moved into a new, state-of-the-art facility as of June 2024, significantly increasing its operational capacity with a newly acquired 48,000 square-foot warehouse. In addition to the expanded headquarters, Stotland Trucking is pleased to announce the opening of its next Texas location in Abilene. This new facility underscores Stotland Trucking’s commitment to growth and service excellence across the state. The company plans to be operational statewide including the Houston market by the end of 2024. The recent expansion is not only physical but also operational, with Stotland Trucking increasing its workforce by nearly 40% to support the growing demand for its services. The company’s strategic focus remains on expanding into new cities, acquiring new customers, and establishing long-term relationships within the logistics industry. “We are excited about the opportunities that come with this expansion,” said Derik Stotland, President of Stotland Trucking LLC. “Our new headquarters and the Abilene location will enable us to enhance our services and meet the needs of our customers more efficiently. Looking ahead, we are dedicated to further expanding our footprint into the Midwest over the next 24 months, bringing our high-quality logistics solutions to new markets.” Stotland Trucking is known for its comprehensive logistics services, including cross-docking, shipping and receiving, final mile delivery, and dedicated transportation. With a reputation for reliability regardless of weather or traffic conditions, the company is poised for continued growth and success. Stotland Trucking is committed to providing dependable, efficient solutions for businesses of all sizes. Tony Torgerud, CEO of Apple Rush, commented “It is exciting to see how Derik has really started to expand this business over the last few months. The pipeline is full and it appears that he will be able to more than double his revenues year over year giving our shareholders a great opportunity with increased shareholder value. We will continue to look for additional complimentary and/or high revenue targets to diversify our holdings and continue building value for all of our partners and stakeholders.” About The Apple Rush Company, Inc. The Apple Rush Company, Inc., through its subsidiary APRU, LLC, is a distributor of CPG products under the trademarked Apple Rush brand, Element brand and other labels. The Apple Rush brand has more than 50 years of existence in the natural beverage industry. As a historical leader in the organic and natural beverage sector our goal is to now become a leader in the distribution of anhydrous hemp oil products nationwide. For more information, please go to www.aprubrands.com, www.element-brands.com, elementk.kratomwave.store www.alkhemicalroots.com with our expanded product portfolio. Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise. For media inquiries, please contact: Investor Relations Contact: Tony Torgerud; 888-741-3777 x 2 www.aprubrands.com Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise. Contact Details Tony Torgerud +1 888-741-3777 dtorgerud@aprullc.com Company Website http://www.aprubrands.com

September 11, 2024 06:54 AM Eastern Daylight Time

Article thumbnail News Release

Aclarion, Inc.’s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector

ACON

As the healthcare technology sector advances, companies are making significant strides in addressing widespread health challenges. One area experiencing notable innovation is the diagnosis and management of chronic low back pain (cLBP), a condition that affects millions globally and incurs substantial healthcare costs. Aclarion, Inc. (NASDAQ: ACON) is emerging as a key player in this field with its groundbreaking Nociscan platform. Nociscan is an advanced diagnostic tool designed to address the global challenge of chronic low back pain, which impacts approximately 266 million people worldwide. This condition is a major driver of healthcare expenditures, with U.S. costs alone reaching up to $134.5 billion annually. Aclarion’s Nociscan platform stands out as the first evidence-supported software-as-a-service (SaaS) solution that uses Magnetic Resonance spectroscopy (MRS), proprietary signal processing techniques, and augmented intelligence algorithms to noninvasively differentiate between painful and nonpainful discs in the lumbar spine. The Nociscan system operates through a cloud-based platform that processes MRI data to quantify chemical biomarkers associated with disc pain. This data is then analyzed using proprietary algorithms to provide physicians with crucial insights into the potential sources of pain. By integrating Nociscan with traditional diagnostic methods, healthcare providers can achieve greater diagnostic precision and enhance treatment planning, leading to improved patient care. Aclarion, Inc. (NASDAQ: ACON) has recently achieved a significant milestone with its Nociscan platform, announcing the completion of the first Nociscan exams in the LIFEHAB trial. This randomized control trial, conducted in Norway, is pivotal in comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain. The trial involves 202 patients and utilized Nociscan’s advanced diagnostic technology to assess how MRS biomarkers can correlate with treatment responses. The LIFEHAB trial began enrollment in Q2 of 2024, and as of late August, six patients have completed their Nociscan exams. Brett Ness, Aclarion’s CEO, highlighted the significance of this development: ““We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient.” This latest achievement showcases ACON’s commitment to advancing chronic low back pain management and demonstrates the growing adoption of Nociscan in research settings. The LIFEHAB trial’s integrations of Nociscan tech represent a crucial step in validating its effectiveness and aligning with Aclarions broader goals of enhaving treatment and outcomes. As ACON continues to make strides, the company has also expended presence in the US market. On August 14, 2024, the company announced a key commercial agreement with Sheridan Community Hospital in Michigan. This partnership marks Aclarion’s entry into central Michigan and involves collaboration with Dr. John Keller, a leading neurosurgeon. This agreement aims to further validate Nociscan’s clinical effectiveness and demonstrates the platform's potential to advance noninvasive, cost-effective diagnostics for disc pain. Building on its success in the UK, where ACON has secured insurance coverage, the company is now focused on achieving similar coverage in the U.S. This is a critical step towards increasing Nociscan’s accessibility and adoption within the American healthcare system. Further expanding its reach, ACON has introduced Nociscan to the personal injury and workers’ compensation markets in New Jersey. Announced on August 29, 2024, this initiative involves Dr. Justin Kubeck, an orthopedic spine surgeon, working to enhance the evaluation of chronic low back pain in these complex legal and insurance settings. This effort aims to provide objective data to support treatment decisions and compensation claims, leveraging Nociscan’s ability to measure biomarkers correlated with pain and structural integrity. In addition to its commercial agreements, Aclarion has launched two major clinical trials to substantiate Nociscan’s benefits. The Clinical Utility and Economic (CLUE) Trial, announced on August 21, 2024, aims to assess how Nociscan’s AI-generated biomarker data impacts surgical treatment decisions. By comparing surgeons’ initial treatment plans with those adjusted after reviewing Nociscan data, the trial seeks to provide valuable real-world evidence of the platform’s effectiveness in improving surgical outcomes. Complementing this, the CLARITY trial—a gold-standard, multicenter, prospective randomized study—will provide definitive evidence on the advantages of incorporating Nociscan data into surgical decision-making processes. Aclarion’s innovative approach has recently garnered industry recognition. On September 5, 2024, ACON was added to the PRISM Emerging Medical Devices Index. This inclusion highlights Aclarion’s position as a leading innovator in the medtech sector. Being part of the PRISM Index validates Aclarion’s technological advancements and can increase its market visibility, credibility, and attractiveness to investors. As the U.S. medical devices market is projected to grow to nearly $315 billion by 2032, Aclarion’s Nociscan is well-positioned to capture a portion of the $40 billion lumbar spine diagnostics and treatment market. ACON’s efforts to address chronic low back pain through innovative, noninvasive technology underscore its potential to make a significant impact in the healthcare sector. With its expanding clinical partnerships, ongoing trials, and recent industry recognition, ACON is positioning itself strongly within the healthcare technology market. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

September 11, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

Alvarez & Marsal Report: Top Private Brand Retailers Outperform the Market: 7 out of Top 10 Retailers by Grocery Dollar Share Are Top Private Brand Players

Alvarez & Marsal Consumer and Retail Group

· U.S. Private Label spending is 20% of total market, projected to rise to 24% by 2030 · Top 4 Private Brand retailers had 144% stock price growth in past 5 years · Over 250 new stores have been opened by top Private Brand retailers in the past year Global professional services firm Alvarez & Marsal’s Consumer and Retail Group (A&M CRG) has released its latest report, Accelerate your Private Brand journey to win with customers and shareholders, which looks at how the Private Label market is accelerating even amid slower total grocery market growth, and what retailers need to do to gain and maintain success with their private brands. The report lays out the case for private label traction as a strategic imperative for grocers and provides examples of the ways in which prominent Private Brand retailers have built stronger loyalty and advocacy with their customers while delivering superior returns for their shareholders. “There’s a strong correlation between the most successful private brand grocers and their market share and financial performance,” noted Marco Valentini, Managing Director at Alvarez & Marsal’s Consumer and Retail Group. “The best players act differently from the rest of the pack. Their C-level executives are committed to growing their own brands and driving differentiation through them. Chief Merchants treat their Private Brands with the same priority and attention as they do National Brands. Marketing and branding efforts are aimed at elevating and differentiating products and increasing overall customer awareness and advocacy of their brands. Finally, product innovation cycles need to reflect the yearly cadence of line reviews and retailers must be able to constantly innovate and update their ‘Own Brand’ products.” The report lays out key enablers to winning with private brands, and the benefits of having a Private Brand strategy, including: · Value perception: Private Brand products should be 30 to 50% less expensive than National Brands and provide same or better quality. The majority of consumers cite value as a key driver of purchase. · Product innovation/differentiation: Private Brand products can be tailored to align with customer demographics and preferences. The second most important attribute that drives purchase of private brands is quality/taste. · Margin management: Private Brand margins typically surpass those of National Brands and the individual product should provide the same or better unit economics (“penny profit”) than their National Brand equivalents. Private Brands are a very effective way to drive value for customers in addition to price and promotion investment, which often dilute margins. · Brand development: More than 8 in 10 shoppers make decisions based on brand trust, so developing private label brands that resonate with consumers and provide strong advocacy is critical. Successful Private Brands can drive positive impact to retailers’ overall banner brand perception. · Sustainable sourcing: Direct control over product development, packaging, sourcing and supply chain can support specific sustainability goals. This is an important factor, especially for Gen Z and Millennial shoppers. "For many grocery retailers today, the lack of a comprehensive Private Brand strategy means that they’ll get left behind,” said John Clear, Senior Director in Alvarez & Marsal’s Consumer and Retail Group. “To unlock the value of private label, grocers need to have a clear plan in place: a differentiated brand architecture and consistent positioning across categories; scalable processes and innovation capabilities that will ensure their success is repeatable.” To download a pdf of Accelerate your Private Brand journey to win with customers and shareholders, please visit: https://alvarezandmarsal-crg.com/insight/accelerate-your-private-brand-journey-to-win-with-customers-and-shareholders/ The Alvarez and Marsal Consumer and Retail Group (CRG) is a management consulting firm that tackles the most complex challenges and advances its clients, people, and communities toward their maximum potential. CRG combines the best of A&M’s broader firm bias toward action and practicality with deep consumer and retail industry experience. CRG partners with businesses across a wide range of categories including Grocery, Mass, Convenience, Discount/Dollar, Wholesale/Distribution, Food & Beverage, Beauty & Personal Care, and Apparel & Footwear to drive significant performance improvement. Contact Details David Schneidman dschneidman@alvarezandmarsal.com Company Website https://www.alvarezandmarsal.com/industries/retail/retail

September 10, 2024 02:00 PM Eastern Daylight Time

Article thumbnail News Release

National Land Realty Finds Acreage Prices Remain Stable Through First Semester

National Land Realty

National Land Realty (NLR), the nation's fastest-growing land brokerage firm specializing in farm, ranch, country estates, timber, recreational, and commercial development properties, has released its latest data on land sales across the United States. The report draws from NLR’s network of over 400 agents and brokers in 48 states to provide a year-to-date analysis of Q1 and Q2 agricultural land sales for 2024. It demonstrates stability in the national aggregate for average price per acre (PPA), while highlighting notable trends within outliers like Louisiana, Florida, and California. National Aggregate The data from NLR’s latest report showed that the average price per acre across the country remained relatively stable, having increased by only about 5% nationally. This comes in the wake of significant farmland appreciation over the past few years, with many parts of the country seeing record prices for farmland in 2023. “Land prices have remained high in spite of increased input costs and interest rates, indicating significant demand across the country for irrigated and available farmland. This is largely due to massive consumer demand for produce, meat, dairy, and feed,” said Ronnie Richardson, CEO at NLR. “While further increases are unlikely for the moment, I believe these values will remain strong for the foreseeable future—barring extensive drought, natural disasters, or an industry-shaking event akin to the COVID-19 pandemic.” Louisiana According to NLR, the data found that the average price per acre in Louisiana decreased by $10,866, primarily due to some of the larger landowners beginning to divest themselves of some farmland holdings. “Louisiana is largely farmland, where land values are influenced by the same forces as elsewhere: supply and demand. Price adjustments occur when production costs rise and commodity prices fall,” said Richardson. “Even with a slight decrease in price per acre, purchasing land remains attractive as divestments create opportunities for buyers to capitalize on economies of scale.” California Data revealed that California's average price per acre dropped by $12,226 over the past year—a significant 27% decline. This decrease is likely driven by a combination of high interest rates and low commodity prices for popular crops like almonds and walnuts. Since prices are relatively high in California overall, percentage-based factors like tax or interest-rate hikes hit the California market harder than they do other states. “Reports of an exodus from California real estate have little implications for the agricultural market, which remains generally unaffected by geopolitics. Taxes and interest rates are far more likely to influence the market,” said Richardson. “We do have a couple of large institutional investors looking to exit the California farmland market, but there are no buyers thus far. They may need to adjust their prices to match demand if they are serious about liquidating. With the average price per acre already down, I'd recommend watching the market closely and holding off on purchases for now." Florida In Florida, the average price per acre surged by $24,000 from 2023 to 2024, reflecting a remarkable 118% increase. This significant rise is driven primarily by the soaring demand for land in the state over the past year. Florida remains one of the top destinations for people moving to different states in the US, meaning this demand for available land in Florida isn’t likely to change anytime soon. “It's the same issue here: supply and demand,” said Richardson. “Even though the price per acre is up, I would still recommend buying land in Florida as demand continues to rise. I would focus on transitional properties in particular as more people continue to move into the state. The key to Florida is simple: demand is driving everything." Annex About National Land Realty National Land Realty (NLR) is the nation’s fastest growing real estate land brokerage company specializing in farm, ranch, country estates, timber, recreational, and commercial development properties. Highly regarded for its proprietary land touring technology, Land Tour 360 ®, as well as its GIS land mapping system, LandBase™, which catalogs land data in extremely detailed ways, the company makes it easy to view and zero in on the right property in the right place. Founded in Greenville, S.C. in 2007, NLR has more than 80 offices in 40 states. To learn more visit www.nationalland.com or call (855) 384-5263. Methodological Note The data in the report was derived from a compilation of land sales data provided by National Land Realty’s network of agents across the United States. The report compares 2023 sales data to sales data from the first half of 2024. For the first half of 2024, the data is based on 6,963 land transactions. Note to the editors A table with data for all states where National Land operates is available in the annex. A headshot of Ronnie Richardson, the company logo, and a map illustrating the states where land values are appreciating or depreciating the most can be accessed via this link. Contact Details Razor Sharp PR Jo Detavernier +1 210-803-2097 jo@razorsharppr.com Company Website https://nationalland.com/

September 10, 2024 09:30 AM Central Daylight Time

Article thumbnail News Release

TRON, Tether, and TRM Labs Establish First-Ever Private Sector Financial Crime Unit to Combat Crypto Crime

TRON DAO

Singapore — September 10, 2024 — TRON, Tether, and TRM Labs today announced they have joined forces to establish the T3 Financial Crime Unit (T3 FCU), a first-of-its-kind initiative aimed at facilitating public-private collaboration to combat illicit activity associated with the use of USDT on the TRON blockchain. This novel collaboration brings together the anti-financial crime expertise of TRM Labs, a leading blockchain intelligence firm; the technical expertise of TRON, a leading global blockchain and DAO; and external investigations team at Tether, the largest company in the digital asset industry, to create a safer and more secure crypto community for all. In the weeks since launch, the initiative, in collaboration with law enforcement, facilitated the freezing of over USDT 12 million in funds associated with a blackmail scam, an investment fraud scheme, and others. Police are aware of at least 11 victims impacted by the scams and expect to identify additional victims as the investigations unfold. Stablecoins like USDT serve as the backbone of the digital asset industry, providing a stable store of value and enabling seamless movement of funds between platforms. With over $117 billion USD in market capitalization and more than 50% of its circulating supply running on the TRON blockchain, USDT is integral to facilitating transactions and liquidity. However, the same features that make USDT on TRON attractive to legitimate users — low fees, lack of volatility, and ease of use — have also drawn the attention of scammers, terrorist financiers, and other threat actors. And as the TRON blockchain's popularity and user base grow, drawn by its high throughput and low transaction costs, so too does its uninvited exposure to these criminal elements. The establishment of the T3 FCU represents a significant step towards impeding the ability of malicious actors to launder and utilize the proceeds of crime, safeguarding the integrity of the TRON blockchain. As part of the collaboration, TRM will provide ongoing support to TRON and Tether in identifying transactions that have a connection to alleged illegal activities such as terrorism, sanctions evasion, theft, hacking, cybercrime, and fraud. TRM will leverage its proprietary technology as well as its global network of expert investigators to generate intelligence. The work will support TRON’s and Tether’s efforts to disrupt criminal activity and aid collaborations with law enforcement around the world. By collaborating to proactively identify and disrupt illicit activity, the T3 FCU aims to promote security and prosperity across the TRON network and beyond. “TRON originated with the belief that technology can be used for good and to empower people across the globe,” said Justin Sun, founder of the TRON blockchain. “By collaborating with TRM Labs and Tether, TRON is helping to ensure that blockchain technology is used to make our world a better place, and sends a clear message that illicit activity is not welcome in our industry.” "At Tether, safeguarding the integrity of the blockchain ecosystem is a top priority and a responsibility we embrace with being a key player in the digital asset space. This commitment drives us to take proactive measures in helping maintain the security and trustworthiness of the ecosystem," said Paolo Ardoino, CEO of Tether. "We’re proud to have worked with TRM Labs and TRON in this pioneering effort. This collaboration underscores our dedication to joining with industry leaders and law enforcement to combat illicit activity, ensuring a secure environment for all users." “As adoption of stablecoins continues to rise, it’s critical that key industry players proactively evolve their capabilities to combat illicit activity and ensure a safe and secure environment,” said Chris Janczewski, head of global investigations at TRM Labs. “TRM is proud to collaborate with TRON, Tether, law enforcement, and others who are committed to helping build a safer blockchain industry for all.” About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the integration of BitTorrent, a pioneer in decentralized Web3 services, boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of August 2024, it has over 247 million total user accounts on the blockchain, more than 8 billion total transactions, and over $22 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Media contact: press@tron.network About Tether Tether is a pioneer in the field of stablecoin technology, driven by an aim to revolutionize the global financial landscape. With a mission to provide accessible and efficient financial, communication, artificial intelligence and energy infrastructure. Tether enables greater financial inclusion, and communication resilience, fosters economic growth, and empowers individuals and businesses alike. As the creator of the largest, most transparent, and liquid stablecoin in the industry, Tether is dedicated to building sustainable and resilient infrastructure for the benefit of underserved communities. By leveraging cutting-edge blockchain and peer-to-peer technology, it is committed to bridging the gap between traditional financial systems and the potential of decentralized finance. Media contact: press@tether.to About TRM Labs TRM Labs provides blockchain intelligence to help law enforcement and national security agencies, financial institutions, and cryptocurrency businesses detect, investigate, and disrupt crypto-related fraud and financial crime. TRM’s Blockchain Intelligence platform includes solutions to follow the money, identify illicit activity, build cases, and construct an operating picture of threats. TRM is trusted by a growing number of leading agencies worldwide who rely on TRM for their blockchain intelligence needs. TRM is based in San Francisco, CA, and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com. Media contact: press@trmlabs.com Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

September 10, 2024 10:15 AM Eastern Daylight Time

Image
Article thumbnail News Release

Anthony Milewski Shares His Insights on Junior Mining Stocks

MarketJar

The Oregon Group continues to lead the conversation in market speculation with its latest insights into the junior mining sector. In the latest "Greed, Guts and Glory" newsletter, founder Anthony Milewski delves into the unique challenges and opportunities within this high-stakes arena, framing junior miners as a bold and strategic choice in a high-stakes environment, comparable to the complexities of trading options. Available on The Oregon Group platform, this newsletter is more than just a publication—it's a community. "Greed, Guts and Glory" is designed to build a network of like-minded speculators, offering a space for exchanging ideas, refining strategies, and celebrating market successes. The Strategic Insight: Junior Miners as Options Trades In the volatile world of commodities, success often depends on timing and strategy. Anthony Milewski, with his decades of experience in the sector, offers a fresh perspective on investing in junior mining companies. Instead of viewing these stocks as traditional equity investments, Milewski suggests that they should be approached as "call options" on large, out-of-the-money deposits. Much like options, junior mining stocks come with a significant amount of risk, primarily due to their reliance on commodity price movements and the inevitable need for capital raises. However, this risk also brings the potential for outsized rewards when the timing is right. The key, as Milewski emphasizes, is understanding the underlying commodity and recognizing the signs of an impending market shift. Understanding the Risks and Rewards The junior mining space is notoriously speculative. With only one in three thousand exploration projects ever evolving into a viable mine, the odds are clearly stacked against investors. However, as Milewski points out, it’s this very risk that creates the possibility for exponential returns. For those willing to embrace this high-risk, high-reward dynamic, the approach is clear: buy the dream, capitalize on a favorable commodity move, and sell at the peak of market enthusiasm. This strategy mirrors the approach taken by options traders, where timing is everything, and the ability to exit before the value erodes is crucial. The Importance of Commodity Cycles Central to this strategy is the understanding of commodity cycles. As Milewski notes, the value of a junior mining stock is heavily influenced by the price of the underlying commodity. At a certain price point, any project can become viable, but below that threshold, even the most promising projects may falter. By recognizing where a specific commodity is in its cycle, investors can better gauge when to enter and exit positions in junior mining stocks. This timing, combined with a deep understanding of the project’s potential and its leverage to the commodity, forms the crux of successful speculation in this space. Leveraging Low-Grade Deposits for High Returns Milewski also highlights the potential hidden in large, low-grade deposits that are often overlooked by the market. These projects, while not immediately attractive due to their lower grades, can become highly valuable as commodity prices rise. This leverage to commodity price movements is where significant wealth can be generated. Robert Friedland, a prominent figure in mining, famously stated that “grade doesn’t matter,” a sentiment echoed by Milewski. He argues that it’s just as challenging to permit and develop a small project as it is a large one, so if you’re going to invest, it’s wise to focus on the bigger opportunities with the potential for substantial returns. Timing the Market: A Fine Art Ultimately, the success of this strategy hinges on timing the market correctly. Entering too early can lead to erosion of value due to ongoing capital raises, while waiting too long may mean missing out on the rapid appreciation that can occur as commodity prices shift. The Oregon Group ’s approach is to constantly evaluate these opportunities, focusing first on the commodity and then on the companies with the best leverage to that commodity. While the path to success in junior mining stocks is fraught with risk, the potential rewards make it a compelling consideration for those with the experience and insight to navigate it. A New Perspective on Junior Mining Investments The Oregon Group ’s latest insights offer a compelling framework for understanding and investing in the junior mining sector. By approaching these stocks as options trades, with a clear focus on timing and commodity leverage, investors can position themselves to potentially reap significant rewards. However, as with all speculative investments, the importance of discipline, timing, and a thorough understanding of the market cannot be overstated. For those ready to explore this high-risk, high-reward strategy, staying informed and connected with experts like Anthony Milewski and The Oregon Group will be crucial to navigating this complex market successfully. For more insights, visit The Oregon Group's website at www.theoregongroup.com or follow them on LinkedIn and Twitter. To stay connected with Anthony Milewski, visit www.anthonymilewski.com or follow him on Twitter/X. Follow The Oregon Group on LinkedIn and Twitter. Disclaimer  1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.  2) The Article was issued on behalf of and sponsored by, The Oregon Group. Market Jar Media Inc. has or expects to receive from The Oregon Group’s Digital Marketing Agency of Record (Native Ads Inc) one thousand five hundred USD for this article.  3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy  4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com  5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.  6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding The Oregon Group.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to The Oregon Group.’s industry; (b) market opportunity; (c) The Oregon Group’s business plans and strategies; (d) services that The Oregon Group intends to offer; (e) The Oregon Groups milestone projections and targets; (f) The Oregon Group’s expectations regarding receipt of approval for regulatory applications; (g) The Oregon Group’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) The Oregon Group’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute The Oregon Group’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) The Oregon Group’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) The Oregon Group’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) The Oregon Group’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of The Oregon Group to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) The Oregon Group’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact The Oregon Group’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing The Oregon Group’s business operations (e) The Oregon Group may be unable to implement its growth strategy; and (f) increased competition.  Except as required by law, The Oregon Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does The Oregon Group nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither The Oregon Group nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.  7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of The Oregon Group or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of The Oregon Group or such entities and are not necessarily indicative of future performance of The Oregon Group or such entities.  8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

September 10, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

PathAI Launches MET Predict on AISight to Enhance NSCLC Assessments

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict † on the AISight Ⓡ † Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image. NSCLC accounts for approximately 85% of lung cancers 1, with 3–4% of these cases involving METex14 2. Today, approved targeted therapies are available for patients with NSCLC who harbor METex14 mutations. Additionally, MET amplification occurs in 1–6% of NSCLC cases 3 and is emerging as a potential biomarker in lung cancer. Traditional molecular testing for MET alterations such as exon 14 skipping or amplification is often hindered by high costs, time- and tissue-consuming procedures, and the need for specialized equipment and trained personnel. These factors limit its accessibility and scalability, prompting the need for more efficient and cost-effective methods to assess MET alterations. “The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.” MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies >90% of MET altered tumors while additionally providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low. With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. †:MET Predict and AISight are for Research Use Only. Not for use in diagnostic procedures. References: 1 American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/what-is.html​ 2 Frampton, G. M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer discovery, 5(8), 850-859.​ 3 Wolf J., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583 About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions, dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 10, 2024 10:00 AM Eastern Daylight Time

Image
1 ... 5455565758 ... 3764